Analogues de la gonadoréline associée aux antiandrogènes dans le traitement des métastases osseuses du cancer de la prostate: leur utilisation peut-elle induire une ostéoporose? = LH-RH analogues combined with anti-androgens in the treatment of bone metastases from prostate carcinomaSIMONIN, R; NICOLINO-PELTIER, C; GAINLET, P et al.La Presse médicale (1983). 1989, Vol 18, Num 41, issn 0755-4982, 2023 [1 p.]Article

Synthesis of novel Gn-RH analogues using Ugi-4MCRARABANIAN, Armin; MOHAMMADNEJAD, Mahdieh; BALALAIE, Saeed et al.Bioorganic & medicinal chemistry letters (Print). 2009, Vol 19, Num 3, pp 887-890, issn 0960-894X, 4 p.Article

Hormonal contraception for human males : prospectsREDDY, P. R. K.Asian journal of andrology. 2000, Vol 2, Num 1, pp 46-50, issn 1008-682XArticle

Role of different GnRH agonist regimens in pituitary suppression and the outcome of controlled ovarian hyperstimulationFILICORI, M; COGNIGNI, G. E; ARNONE, R et al.Human reproduction (Oxford. Print). 1996, Vol 11, pp 123-132, issn 0268-1161, SUP3Article

Specific gonadotrophin-releasing hormone analogue binding predominantly in human luteinized follicular aspirates and not in human pre-ovulatory folliclesBRUS, L; LAMBALK, C. B; DE KONING, J et al.Human reproduction (Oxford. Print). 1997, Vol 12, Num 4, pp 769-773, issn 0268-1161Article

DIE KAPILLARISOTACHOPHORESE - EINE NEUE METHODE IN DER ARZNEIMITTELANALYTIK = L'ISOTACHOPHORESE CAPILLAIRE: UN NOUVEAU PROCEDE DANS L'ANALYSE DES MEDICAMENTSJANNASCH R.1983; PHARMAZIE; ISSN 0031-7144; DDR; DA. 1983; VOL. 38; NO 6; PP. 379-387; ABS. ENG; BIBL. 29 REF.Article

Gonadorelin-induced testosterone release : A biological assay for quality assurance of gonadorelin in veterinary medicineKESLER, D. J; SUMMERS, R. N; PETERSON, C. A et al.Drug development and industrial pharmacy. 1999, Vol 25, Num 3, pp 315-321, issn 0363-9045Article

Reversibility of androgen deprivation therapy in patients with prostate cancerFRIDMANS, Alon; CHERTIN, Boris; KOULIKOV, Dmitry et al.The Journal of urology. 2005, Vol 173, Num 3, pp 784-789, issn 0022-5347, 6 p.Article

Osteoporosis and obesity in men receiving hormone therapy for prostate cancer. DiscussionSMITH, Matthew R; KLOTZ, Laurence; CARROLL, Peter R et al.The Journal of urology. 2004, Vol 172, Num 5, pp S52-S57, issn 0022-5347, 2Conference Paper

Degradation kinetics of gonadorelin in aqueous solutionHOITINK, M. A; BEIJNEN, J. H; BULT, A et al.Journal of pharmaceutical sciences. 1996, Vol 85, Num 10, pp 1053-1059, issn 0022-3549Article

Endocrine/reproductive pulsatile delivery systemsCREASY, G. W; JAFFE, M. E.Advanced drug delivery reviews. 1991, Vol 6, Num 1, pp 51-56, issn 0169-409X, 6 p.Article

Déclenchement de l'ovulation par les analogues de la gonadoreline: vers une réduction du risque d'hyperstimulation ovarienne?EMPERAIRE, J. C.La Presse médicale (1983). 1990, Vol 19, Num 10, pp 473-474, issn 0755-4982Article

Raloxifene and Antiestrogenic Gonadorelin Inhibits Intestinal Tumorigenesis by Modulating Immune Cells and Decreasing Stem-like CellsJANAKIRAM, Naveena B; MOHAMMED, Altaf; BREWER, Misty et al.Cancer prevention research (Philadelphia, Pa.). 2014, Vol 7, Num 3, pp 300-309, issn 1940-6207, 10 p.Article

Preparation and properties of selected Zn(II)-peptide complexes in suspensionDOLINSKA, Barbara; RYSZKA, Florian.Il Farmaco (Pavia). 2003, Vol 58, Num 11, pp 1131-1136, issn 0014-827X, 6 p.Article

Identification of the degradation products of gonadorelin and three analogues in aqueous solutionHOLTINK, M. A; BEIJNEN, J. H; BOSCHMA, M. U. S et al.Analytical chemistry (Washington, DC). 1997, Vol 69, Num 24, pp 4972-4978, issn 0003-2700Article

Gonadoreline release from suspensions with chosen metal ionsDOLINSKA, B; ZIENTARSKA, G; RYSZKA, F et al.Pharmazie. 1995, Vol 50, Num 1, pp 52-53, issn 0031-7144Article

Mass spectrometric determination of gonadotrophin-releasing hormone (GnRH) in human urine for doping control purposes by means of LC-ESI-MS/MSTHOMAS, Andreas; GEYER, Hans; KAMBER, Matthias et al.Journal of mass spectrometry. 2008, Vol 43, Num 7, pp 908-915, issn 1076-5174, 8 p.Article

Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. CommentarySMITH, Matthew R; BOYCE, Simone Peart; MOYNEUR, Erick et al.The Journal of urology. 2006, Vol 175, Num 1, pp 136-139, issn 0022-5347, 4 p.Article

Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancerAPPU, Sree; LAWRENTSCHUK, Nathan; GRILLS, Richard J et al.The Journal of urology. 2005, Vol 174, Num 1, pp 140-142, issn 0022-5347, 3 p.Article

Inverse correlation between baseline inhibin B and FSH after stimulation with GnRH : a study of serum levels of inhibin A and B, pro alpha-C and activin A in women with ovulatory disturbances before and after stimulation with GnRHCASPER, F. W; SEUFERT, R. J; POLLOW, K et al.European journal of endocrinology. 2000, Vol 143, Num 1, pp 77-84, issn 0804-4643Article

Subcutaneous administration of a depot gonadotropin-releasing hormone agonist induces profound reproductive axis suppression in womenFILICORI, M; COGNIGNI, G. E; ARNONE, R et al.Fertility and sterility. 1998, Vol 69, Num 3, pp 443-449, issn 0015-0282Conference Paper

Histréline (VANTAS°) nième agoniste de la gonadoréline, sans plus = Histrelin (VANTAS°): another gonadorelin analogue, no moreLa Revue Prescrire. 2011, Vol 31, Num 336, issn 0247-7750, p. 728Article

Modulatory effects of gonadorelin on GABA-induced depolarization and GABA-activated current in rat spinal ganglion neuronsZHOU, X.-P; WU, X.-P; GUAN, B.-C et al.Zhōngguó yàoli xuébào. 1996, Vol 17, Num 1, pp 31-34, issn 0253-9756Conference Paper

Plasma levels of β-endorphin in white-tailed deer: seasonal variation and the effect of thyroxine, GnRH, dexamethasone and ACTH administrationBUBENIK, G. A; SMITH, J. H; FLYNN, A et al.Comparative biochemistry and physiology. A. Comparative physiology. 1988, Vol 90, Num 2, pp 309-313, issn 0300-9629Article

Bleeding associated with uterine leiomyomas: Tailor treatment to the individual patientPrescrire international (Paris). 2014, Vol 23, Num 149, pp 130-135, issn 1167-7422, 6 p.Article